J C Wasmuth
Overview
Explore the profile of J C Wasmuth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meyerhoff P, Manekeller S, Saleh N, Boesecke C, Schlabe S, Wasmuth J, et al.
Epidemiol Infect
. 2021 Mar;
149:e119.
PMID: 33734061
Rabies post-exposure prophylaxis (R-PEP) including wound treatment, vaccination and application of rabies immunoglobulin (RIG) is essential in preventing rabies mortality. Today, Germany is officially declared free from terrestrial rabies and...
2.
Duerr G, Heine A, Hamiko M, Zimmer S, Luetkens J, Nattermann J, et al.
Life Sci
. 2020 Sep;
260:118400.
PMID: 32918975
Objective: To elucidate prognostic markers to identify patients at risk. Results: Only patients with pericardial effusion (PE) developed a severe disease course, and those who died could be identified by...
3.
Mocroft A, Neesgard B, Zangerle R, Rieger A, Castagna A, Spagnuolo V, et al.
HIV Med
. 2020 Jun;
21(9):599-606.
PMID: 32588958
Objectives: Although outcomes of antiretroviral therapy (ART) have been evaluated in randomized controlled trials, experiences from subpopulations defined by age, CD4 count or viral load (VL) in heterogeneous real-world settings...
4.
Schwarze-Zander C, Piduhn H, Boesecke C, Schlabe S, Stoffel-Wagner B, Wasmuth J, et al.
HIV Med
. 2020 Feb;
21(6):378-385.
PMID: 32065713
Objectives: Development of novel antiretrovirals aims at reducing long-term toxicities. Tenofovir disoproxil fumarate (TDF) has been associated with potential nephrotoxicity. The aim of our study was to assess the impact...
5.
Malin J, Boesecke C, Schwarze-Zander C, Wasmuth J, Schlabe S, Trebicka J, et al.
HIV Med
. 2019 Jan;
20(3):230-236.
PMID: 30687989
Objectives: The aim of the study was to assess the regression of liver stiffness after successful direct-acting antiviral (DAA) treatment in patients with hepatitis C virus (HCV) monoinfection and HCV/-HIV...
6.
Schwarze-Zander C, Draenert R, Lehmann C, Stecher M, Boesecke C, Sammet S, et al.
Epidemiol Infect
. 2016 Oct;
145(2):236-244.
PMID: 27780480
Measles, mumps, rubella (MMR) and varicella zoster virus (VZV) infection can cause serious diseases and complications in the HIV-positive population. Due to successful vaccination programmes measles, mumps and congenital rubella...
7.
Schwarze-Zander C, Pabst S, Hammerstingl C, Ohlig J, Wasmuth J, Boesecke C, et al.
HIV Med
. 2015 May;
16(9):578-82.
PMID: 25960172
Objectives: While idiopathic pulmonary arterial hypertension (PAH) is a rare disease, it is seen more frequently in patients with HIV infection. The aim of this study was to evaluate the...
8.
Kasapovic A, Boesecke C, Schwarze-Zander C, Anadol E, Vogel M, Hippe V, et al.
HIV Med
. 2013 Oct;
15(3):175-81.
PMID: 24127641
Objectives: Because of the improved life expectancy provided by successful antiretroviral combination therapy, preventive health measures in HIV-infected patients have assumed increasing importance. To date, no data exist on rates...
9.
Ehren K, Hertenstein C, Kummerle T, Vehreschild J, Fischer J, Gillor D, et al.
Infection
. 2013 Oct;
42(1):135-40.
PMID: 24081925
Purpose: Causes of death in human immunodeficiency virus (HIV)-infected subjects have changed in countries with high resources over the last several years. Acquired immunodeficiency syndrome (AIDS)-related diseases have become less...
10.
Jansen A, Colbers E, van der Ven A, Richter C, Rockstroh J, Wasmuth J, et al.
HIV Med
. 2013 Mar;
14(7):449-52.
PMID: 23506243
Objectives: To evaluate the use of raltegravir with unboosted atazanavir in combination with one nucleoside reverse transcriptase inhibitor (NRTI) (lamivudine or emtricitabine) as a potentially well-tolerated once-daily (qd) maintenance regimen....